TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02884713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
Study: NCT04079140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by the patient 12 hours before IUD insertion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo self-inserted by the patient 12 hours before IUD insertion.
Study: NCT02564835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
Study: NCT02876601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Defibrotide
Description: 6.25mg/kg bodyweight over 2h infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Defibrotide
Description: 6.25mg/kg bodyweight over 2h infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Description: (0.9% sodium chloride) infusion over 2h infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (0.9% sodium chloride)
Description: (0.9% sodium chloride) infusion over 2h infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: bolus infusion of 2ng/kg bodyweight lps

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipopolysaccharide
Description: bolus infusion of 2ng/kg bodyweight lps

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (0.9% sodium chloride bolus)
Description: (0.9% sodium chloride) bolus infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (0.9% sodium chloride bolus)
Description: (0.9% sodium chloride) bolus infusion
Study: NCT04371458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative providone-iodine lavage
Description: Intraoperative providone-iodine lavage during resection
Study: NCT04234412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood stem cell implantation for osteoarthritis treatment
Description: The arthroscopic procedure is performed in the supine position after spinal anesthesia. Once the chondral lesion is identified through a standard anteromedial and lateral portal, meniscectomy, meniscal repair, and lateral retinacular release are performed if necessary. microfracture is performed using a microfracture awl.~Once both the unstable cartilage and subchondral bone are removed in the lesion area and the sclerotic bone is peeled slightly by using a burr, hole(s) are created for implantation by using a drill bit(diameter 4; depth: 4mm). After implantation is performed in the hole by injecting the mixture of sodium hyaluronate and hUCB-MSCs, it is trimmed to the height of the surrounding articular surface.
Study: NCT01254760

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A multifocal contact lens, investigational
Description: Investigational, soft, multifocal contact lens for daily wear, daily disposable use.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A multifocal contact lens, investigational
Description: Investigational, soft, multifocal contact lens for daily wear, daily disposable use.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A multifocal contact lens, commercial
Description: Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A multifocal contact lens, commercial
Description: Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
Study: NCT00811486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone and conivaptan
Description: Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
Study: NCT02983929

Intervention type: PROCEDURE
Intervention: Rehabilitation after total knee arthroplasty
Description: All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.

Intervention type: PROCEDURE
Intervention: Rehabilitation after total knee arthroplasty
Description: All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
Study: NCT00692263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram and tramadol
Description: 10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo and tramadol
Description: 9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
Study: NCT00974480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin (Rejuva-A)
Description: Tretinoin 0.025% cream.
Study: NCT02329418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explaining withholding and withdrawing life-sustaining therapies along with a written document
Description: The document describes the law and the role of family members and medical team in the decision.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Explaining withholding and withdrawing life-sustaining therapies following standard procedure
Study: NCT02302014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Intervention
Description: Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
Study: NCT01901913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-bolus calculator for pre-meal bolus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No MD-bolus calculator for pre-meal bolus
Study: NCT03311698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition-sensitive intervention
Description: Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
Study: NCT00202878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Description: Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for simvastatin 40 mg
Description: one or two tablets orally daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for simvastatin 40 mg
Description: one or two tablets orally daily
Study: NCT00384046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patch, placebo, patch changed every 3-4 days, 24 weeks
Study: NCT01341613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardioviva™ supplement capsule
Description: Twice per day (BID), 9 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Twice per day (BID), 9 weeks
Study: NCT02923297

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: blood sampling for determine and compare the expression patterns of GALIG gene
Study: NCT00309491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Description: 2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Description: 2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen + Aminoglutethimide
Description: 2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~* 1st therapy week:125mg/-/125mg Aminoglutethimide daily~* 2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~* as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily
Study: NCT01680042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin paste

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04056390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy
Description: Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy
Description: Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.
Study: NCT02644421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02506348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac
Study: NCT03959267

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone Genetic Counseling
Description: A genetic counselor fluent in Spanish (see letter of support) will conduct the TGC. The TGC intervention consists of two sessions. Prior to the sessions the investigators will mail participants the education materials with information to be reviewed prior to the genetic counseling session and a set of visual aids that the counselor will refer to during the session to facilitate the understanding of the information conveyed in the session.
Study: NCT00939393

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FESS instruments with or without balloon treatment
Description: Intervention with metal instruments with or without balloon treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon Sinuplasty
Description: Balloon dilatation of sinuses
Study: NCT01965678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Study: NCT02722083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (BAY X002134)
Description: 4 mg tablet, single dose, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet, single dose, orally
Study: NCT02248246

Intervention type: DEVICE
Group type: OTHER
Intervention: Harmonic ACE®+7 Shears
Description: Vessel sealing performance assessed for transection and sealing of the following named vessels:~* Inferior mesenteric artery (IMA)~* Inferior mesenteric vein (IMV) (if identified)
Study: NCT01671319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel + cyclophosphamide + pegfilgrastim
Description: docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
Study: NCT03083873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145-S1
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145-S1
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with autologous TIL (LN-145-S1) followed by IL-2 administration.
Study: NCT02805829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + NK cells
Description: NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
Study: NCT01399372

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: One 28-day cycle = 500 mg/m\^2 intravenously on day 1 and day 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: One 28-day cycle = 500 mg/m\^2 intravenously on day 1 and day 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: One 28-day cycle = 3 g/m\^2 intravenously on day 1 and day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: One 28-day cycle = 3 g/m\^2 intravenously on day 1 and day 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: One 28-day cycle = 3.5 g/m\^2 intravenously (standard hydration/leucovorin support) on day 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procarbazine
Description: One 28-day cycle = 100 mg/m\^2 orally on days 2-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: One 28-day cycle = 100 mg/m\^2 orally on days 2-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: One 28-day cycle = 1.4 mg/m\^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: One 28-day cycle = 1.4 mg/m\^2 intravenously, dose capped at 2.4mg, on day 2 and day 16.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose whole-brain radiation therapy
Description: Total dose of 2340 cGy administered as 13 daily fractions of 180 cGy over 3 weeks. Participants with progressive disease on magnetic resonance imaging (MRI) do not receive WBRT.
Study: NCT03470844

Intervention type: BEHAVIORAL
Intervention: Face-to-face neurocognitive tests
Description: Assessment of attention, processing speed, working memory and executive function

Intervention type: BEHAVIORAL
Intervention: Face-to-face neurocognitive tests
Description: Assessment of attention, processing speed, working memory and executive function

Intervention type: BEHAVIORAL
Intervention: Face-to-face neurocognitive tests
Description: Assessment of attention, processing speed, working memory and executive function

Intervention type: BEHAVIORAL
Intervention: Face-to-face neurocognitive tests
Description: Assessment of attention, processing speed, working memory and executive function

Intervention type: BEHAVIORAL
Intervention: Psychological screening
Description: Screening for the symptoms of depression, anxiety and post-traumatic stress disorder

Intervention type: BEHAVIORAL
Intervention: Psychological screening
Description: Screening for the symptoms of depression, anxiety and post-traumatic stress disorder

Intervention type: BEHAVIORAL
Intervention: Psychological screening
Description: Screening for the symptoms of depression, anxiety and post-traumatic stress disorder

Intervention type: BEHAVIORAL
Intervention: Psychological screening
Description: Screening for the symptoms of depression, anxiety and post-traumatic stress disorder

Intervention type: OTHER
Intervention: fMRI
Description: Brain volume, chemical markers, functional outcome

Intervention type: OTHER
Intervention: fMRI
Description: Brain volume, chemical markers, functional outcome

Intervention type: OTHER
Intervention: fMRI
Description: Brain volume, chemical markers, functional outcome

Intervention type: OTHER
Intervention: fMRI
Description: Brain volume, chemical markers, functional outcome

Intervention type: BEHAVIORAL
Intervention: Quality of Life Self-Assessment data
Description: EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs

Intervention type: BEHAVIORAL
Intervention: Quality of Life Self-Assessment data
Description: EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs

Intervention type: BEHAVIORAL
Intervention: Quality of Life Self-Assessment data
Description: EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs

Intervention type: BEHAVIORAL
Intervention: Quality of Life Self-Assessment data
Description: EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs
Study: NCT02569749

Intervention type: OTHER
Intervention: Berlin and Epworth questionaries

Intervention type: OTHER
Intervention: Berlin and Epworth questionaries

Intervention type: OTHER
Intervention: Berlin and Epworth questionaries

Intervention type: OTHER
Intervention: Berlin and Epworth questionaries

Intervention type: OTHER
Intervention: Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.

Intervention type: OTHER
Intervention: Night polygraph / Polysomnography

Intervention type: OTHER
Intervention: Night polygraph / Polysomnography

Intervention type: OTHER
Intervention: Night polygraph / Polysomnography

Intervention type: OTHER
Intervention: Night polygraph / Polysomnography
Study: NCT03098732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetically Enhanced Diffusion (MED)
Description: Treatment of Acute Ischemic Stroke with IV tPA and the adjunctive Magnetically Enhanced Diffusion (MED) System Procedure.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MED Workstation Magnet Sham Control
Description: Treatment of Acute Ischemic Stroke with IV tPA and Sham use of the MED Workstation only, without the injection of MED MicroBeads.
Study: NCT02905227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-427 (zolmitriptan inhalation powder)
Description: Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-427 (zolmitriptan inhalation powder)
Description: Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-427 (zolmitriptan inhalation powder)
Description: Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
Study: NCT02617472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic floor exerciser
Description: Daily exercise using the study device